Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
BMB Rep ; 54(2): 106-111, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-32843130

RESUMO

Hemistepsin A (HsA) is a guaianolide sesquiterpene lactone that inhibits hepatitis and liver fibrosis. We evaluated the effects of HsA on liver X receptor (LXR)-mediated hepatic lipogenesis in vitro and in vivo. Up to 10 µM, HsA did not affect the viability of HepG2 and Huh7 cells. Pretreatment with 5-10 µM HsA significantly decreased the luciferase activity of the LXR response element, which was transactivated by T0901317, GW 3965, and LXRα/retinoid X receptor α overexpression. In addition, it significantly inhibited the mRNA expression of LXRα in HepG2 and Huh7 cells. It also suppressed the expression of sterol regulatory element-binding protein-1c and lipogenic genes and reduced the triglyceride accumulation triggered by T0901317. Intraperitoneal injection of HsA (5 and 10 mg/kg) in mice significantly alleviated the T0901317-mediated increases in hepatocyte diameter and the percentage of regions in hepatic parenchyma occupied by lipid droplets. Furthermore, HsA significantly attenuated hepatic triglyceride accumulation by restoring the impaired expression of LXRα-dependent lipogenic genes caused by T0901317. Therefore, based on its inhibition of the LXRα-dependent signaling pathway, HsA has prophylactic potential for steatosis. [BMB Reports 2021; 54(2): 106-111].


Assuntos
Hidrocarbonetos Fluorados/antagonistas & inibidores , Lactonas/farmacologia , Lipogênese/efeitos dos fármacos , Fígado/efeitos dos fármacos , Sesquiterpenos/farmacologia , Sulfonamidas/antagonistas & inibidores , Células Cultivadas , Humanos , Hidrocarbonetos Fluorados/farmacologia , Fígado/metabolismo , Receptores X do Fígado/antagonistas & inibidores , Receptores X do Fígado/genética , Receptores X do Fígado/metabolismo , Sulfonamidas/farmacologia
2.
J Pharmacol Sci ; 125(2): 169-75, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24859780

RESUMO

Hypoxia or hypoxia/reoxygenation impairs nitric oxide (NO)-mediated relaxation through the increase in superoxide generation in monkey coronary arteries. Soluble guanylate cyclase (sGC), the target enzyme of NO, has been shown to change from the NO-sensitive reduced form to the NO-insensitive oxidized/heme-free form under substantial oxidative stress, so the present study investigated whether hypoxia or hypoxia/reoxygenation influences sGC redox equilibrium. In isolated monkey coronary arteries without endothelium, the relaxation caused by the sGC stimulator BAY 41-2272 (Emax: 93.3% ± 2.2%) was somewhat impaired under hypoxia (Emax: 86.3% ± 2.6%) or hypoxia/reoxygenation (Emax: 86.1% ± 3.2%), whereas that by the sGC activator BAY 60-2770 (Emax: 86.0% ± 3.2%) was significantly augmented under hypoxia (Emax: 94.4% ± 1.3%) or hypoxia/reoxygenation (Emax: 95.5% ± 1.1%). In addition, cGMP formation in response to BAY 41-2272 and BAY 60-2770 was inhibited and stimulated, respectively, under hypoxia or hypoxia/reoxygenation. The effects of hypoxia or hypoxia/reoxygenation on BAY 41-2272- and BAY 60-2770-induced vasorelaxation were completely canceled by the treatment with the superoxide dismutase mimetic tempol. These findings suggest that sGC redox equilibrium in the coronary artery is shifted towards the NO-insensitive form under hypoxia or hypoxia/reoxygenation and that superoxide seems to play an important role in this shift.


Assuntos
Vasos Coronários/enzimologia , Vasos Coronários/fisiopatologia , Guanilato Ciclase/metabolismo , Hipóxia/enzimologia , Hipóxia/fisiopatologia , Superóxidos/metabolismo , Vasodilatação , Animais , Benzoatos/antagonistas & inibidores , Benzoatos/farmacologia , Compostos de Bifenilo/antagonistas & inibidores , Compostos de Bifenilo/farmacologia , Vasos Coronários/metabolismo , GMP Cíclico/metabolismo , Feminino , Hidrocarbonetos Fluorados/antagonistas & inibidores , Hidrocarbonetos Fluorados/farmacologia , Hipóxia/metabolismo , Técnicas In Vitro , Macaca , Masculino , Óxido Nítrico/metabolismo , Óxido Nítrico/fisiologia , Oxirredução , Estresse Oxidativo , Pirazóis/antagonistas & inibidores , Pirazóis/farmacologia , Piridinas/antagonistas & inibidores , Piridinas/farmacologia , Solubilidade , Superóxido Dismutase/farmacologia , Vasodilatação/efeitos dos fármacos
3.
AAPS J ; 15(3): 744-52, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23591747

RESUMO

Liver X receptor (LXR) has been identified as a potential target for treatment of atherosclerosis and diabetes. Activation of LXR, however, is associated with increased lipogenesis and fat accumulation in the liver. The objective of the current study was to examine the effect of resveratrol on LXR activator-induced fat accumulation in liver using mice as an animal model. Three groups of C57BL/6 mice were studied. Animals in group 1 were treated with T0901317, a potent activator of LXR in mice. Animals in group 2 served as the control and were treated with carrier solution and those in group 3 were treated with T0901317/resveratrol combination. Using histochemical and biochemical methods, we demonstrate that resveratrol treatment significantly suppressed fat accumulation in the liver induced by T0901317. In addition, resveratrol completely blocked elevation of blood levels of triglyceride and cholesterol and reduced blood glucose level. Quantitative PCR analysis revealed that resveratrol treatment did not change the mRNA levels of abca1, abcg1, cyp7a1, srebp-1c, chrebp, and acc genes compared to that of animals treated with T0901317 alone but reduced pepck and g6p gene expressions. Immunohistochemistry and Western blot analyses show resveratrol treatment activated AMP-activated protein kinase (AMPK) and increased phosphorylation of acetyl-CoA carboxylase. Treatment with T0901317 on hepatocytes increased intracellular fat accumulation and this increase was suppressed by resveratrol; the suppressive effect of resveratrol was greatly repressed by Compound C which is an inhibitor of AMPK. Collectively, these data suggest that resveratrol blocks T0901317-induced lipid accumulation in the liver and can be considered for inclusion into the treatment of diseases involving activation of liver X receptor.


Assuntos
Fígado Gorduroso/induzido quimicamente , Fígado Gorduroso/tratamento farmacológico , Hidrocarbonetos Fluorados/toxicidade , Estilbenos/uso terapêutico , Sulfonamidas/toxicidade , Animais , Células Cultivadas , Fígado Gorduroso/metabolismo , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Hidrocarbonetos Fluorados/antagonistas & inibidores , Receptores X do Fígado , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Receptores Nucleares Órfãos/agonistas , Receptores Nucleares Órfãos/metabolismo , Resveratrol , Estilbenos/farmacologia , Sulfonamidas/antagonistas & inibidores
4.
Antioxid Redox Signal ; 14(5): 733-45, 2011 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-20677908

RESUMO

Liver X receptor-α (LXRα) functions as a major regulator of lipid homeostasis through activation of sterol regulatory element binding protein-1c (SREBP-1c), which promotes hepatic steatosis and steatohepatitis. NF-E2-related factor 2 (Nrf2) is the crucial transcription factor that is necessary for the induction of antioxidant enzymes. This study investigated the potential of liquiritigenin (LQ), a hepatoprotective flavonoid in licorice, to inhibit LXRα-induced hepatic steatosis, and the underlying mechanism of the action. LQ treatment attenuated fat accumulation and lipogenic gene induction in the liver of mice fed a high fat diet. Also, LQ had the ability to inhibit oxidative liver injury, as shown by decreases in thiobarbituric acid reactive substances formation and nitrotyrosinylation. Moreover, LQ treatment antagonized LXRα agonist (T0901317)-mediated SREBP-1c activation, and transactivation of the lipogenic target genes. LQ was found to activate Nrf2, and the ability of LQ to inhibit LXRα-mediated SREBP-1c activation was reversed by Nrf2 deficiency, which supports the inhibitory role of Nrf2 in LXRα-dependent lipogenesis. Consistently, treatment with other Nrf2 activators or forced expression of Nrf2 also inhibited LXRα-mediated SREBP-1c activation. Our results demonstrate that LQ has an efficacy to activate Nrf2, which contributes to inhibiting the activity of LXRα that leads to SREBP-1c induction and hepatic steatosis.


Assuntos
Fígado Gorduroso/patologia , Flavanonas/farmacologia , Fator 2 Relacionado a NF-E2/metabolismo , Receptores Nucleares Órfãos/antagonistas & inibidores , Receptores Nucleares Órfãos/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Animais , Antioxidantes/farmacologia , Linhagem Celular , Gorduras na Dieta/metabolismo , Regulação da Expressão Gênica/efeitos dos fármacos , Regulação da Expressão Gênica/genética , Glycyrrhiza/química , Células Hep G2 , Humanos , Hidrocarbonetos Fluorados/antagonistas & inibidores , Hidrocarbonetos Fluorados/metabolismo , Lipogênese/genética , Fígado/efeitos dos fármacos , Fígado/metabolismo , Fígado/patologia , Receptores X do Fígado , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Receptores Nucleares Órfãos/genética , Ratos , Transdução de Sinais/efeitos dos fármacos , Proteína de Ligação a Elemento Regulador de Esterol 1/antagonistas & inibidores , Proteína de Ligação a Elemento Regulador de Esterol 1/genética , Proteína de Ligação a Elemento Regulador de Esterol 1/metabolismo , Sulfonamidas/antagonistas & inibidores , Sulfonamidas/metabolismo
5.
J Agric Food Chem ; 55(6): 2268-75, 2007 Mar 21.
Artigo em Inglês | MEDLINE | ID: mdl-17311398

RESUMO

White bean (Phaseolus vulgaris L.) was used to study the antagonism caused by Na-bentazon on the phytotoxic action of the sulfonylurea (SU) herbicide tritosulfuron. After 168 h, uptake and translocation of [14C]tritosulfuron were reduced by 60 and 89%, respectively, when Na-bentazon was added to the mixture. Addition of (NH4)2SO4 or replacement of Na-bentazon with NH4-bentazon completely eliminated the negative effects on [14C]tritosulfuron uptake but not on its translocation. Scanning electron microscopy revealed that a mixture of Na-bentazon plus tritosulfuron plus DASH HC (0.156%) formed a rough layer of grain-like crystals on the leaf surface, whereas the addition of (NH4)2SO4 or replacement of Na-bentazon with NH4-bentazon resulted in amorphous deposits that may be more easily absorbed. The antagonism of tritosulfuron's phytotoxicity by Na-bentazon involves two separate processes, chemical (uptake effect) and biochemical (translocation effect).


Assuntos
Benzotiadiazinas/farmacologia , Herbicidas/antagonistas & inibidores , Hidrocarbonetos Fluorados/antagonistas & inibidores , Phaseolus/efeitos dos fármacos , Triazinas/antagonistas & inibidores , Ureia/análogos & derivados , Radioisótopos de Carbono , Herbicidas/farmacologia , Hidrocarbonetos Fluorados/farmacologia , Microscopia Eletrônica de Transmissão , Triazinas/farmacologia , Ureia/antagonistas & inibidores , Ureia/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA